Pharma courses

pharma courses

NMDA receptor inhibitors
Memantine: Excessive NMDA receptor activation can lead to excitatory toxicity and neuronal death. This suggests that memantine blocks pathological stimulation of NMDA receptors may protect against further tissue damage in patients with vascular dementia and possibly Alzheimer’s disease [63].memantine initiated with daily dose is 10 mg twice daily, achieved by a 3-weeks

Antiglutamatergic Therapy
Memantine is the only NMDA receptor antagonist used currently. Memantine blocks glutamatergic neurotransmission by antagonizing NMDA receptors. Glutamate is an excitatory neurotransmitter in the brain it involves in the improvement of learning and memory.(19) Memantine drug can initiated at 5 mg/day and  gradually increased weekly by 5 mg/day to the effective dose of 10 mg twice daily.It may be given with or without food. (23

Most of the dementia patients are manifested by non-cognitive symptoms.they may be categorized as psychotic symptoms, disruptive behavior and depression. Effective treatment of this problem is important to deplete the stress condition and abnormal psychic problems

Depression is a common sign in patients with Alzheimer disease occurring in 50% of patients.the patient who receives the treatment with selective serotonin reuptake inhibitors (SSRIs) shows better therapauetic results in the drugs such as sertaline,citalopram,paroxetine and fluoxetine.(28)  serotonin/ nor-epinephrine reuptake inhibitor such as venlafaxine may be alternative.(24) The drug trazodone prescribed to manage behavioural or depressive symptoms mainly it recommends for patient affected by insomnia with dementia.(25) “Mood stabilizer” anticonvulsants such as carbamazepine or valproic acid may be appropriate alternatives to elevate the mood condition sad into excitated state, but evidence is conflicting.(26

Antipsychotics are widely used in the management of neuropsychiatric symptoms in AD. In this type management shows most of the atypical antipsychotics provide best action for particular neuropsychiatric symptoms. Food and Drug Administration (FDA) approval as an indication for the management of behavioral symptoms in AD. Based on the analysis, 17% to 18% of dementia patients show a treatment response to atypical antipsychotics (27). Neuropsychiatric drug initiated in Dementia is haloperidol (1-3 mg/day), Quetiapine (100-300mg/day), Risperidone (0.75-2mg/day), Ziprasidone (40-160mg/day), and Olanzapine (5-10mg/day). (19, 28, 29)

The Alzheimer disease is irreversible disease, widely the AD treated by Anti-psychotics and Anti-Depressant drugs. This category of drugs acts well versed and shown better results in the persons behavior and prevent the frequent mood changes. The AD people also doesn’t have the sense of their daily activities, All those things are erased from their brain (it denotes Exact unconsciousness).Apart from the drug treatment, the patient should be treated with good humanity by the people who are surrounding them, the family members must be take care in patient health, then only the patient will be survive with their needful.

1. Alzheimer’s disease facts and figures. 2010. http://www.alz.org/documents custom/report alzfactsfigures 2010. Date of accession: 4 Feb 2013.
2. Lezak MD, Howieson DB, Luring DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
3. Goedert M, Spillantini G. A century of Alzheimer’s disease. Science 2006; 314:777–781.
4.Benoit M, Arbus C, Blanchard F, et al. Professional consensus on the  treatment of agitation, aggressive behavior, oppositional behavior and psychotic disturbances in dementia. J Nutr Health Aging 2006; 10:410–415.
5. Alzheimer’s disease International factsheet, The Prevalence of Dementia Worldwide,
6 . A Wimo, B.Winblad, H. Aguero-Torres and E. V. Strauss, The magnitude of Dementia occurrence in the World, Alzheimer Disease and Associated Disorders, 17 (2) (2003), 63–67.
7. Alzheimer’s Association. http://www.alz.org/.
8. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003; 348:1356–1364.
9. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer’s disease in the U.S. population: Prevalence estimates using the 2000 census. Arch Neurol 2003; 60:1119–1122.
10. Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimer’s disease. Neurology 2005; 64 (Supplement 3):S34–S39.
11. Chandra V, Bharucha NE, Schoenberg BS. Conditions associated with Alzheimer’s disease at death: Case-control study. Neurology 1986; 36:209–211.
12. Mohs RC, Haroutunian V. Alzheimer’s disease: From earliest symptoms to end stage. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuro psychopharmacology: The Fifth Generation of Progress. New York: Lippincott Williams & Wilkins, 2002:1189–1198.
13. Boustani M, Peterson B, Hanson L, et al. screening for dementia in primary care: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 138:927–937.
14. Knopman DS, DeKosky ST, and Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143–1153.
15. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer’s  disease with PET. J Nucl Med 1994; 35:391–398.
16. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory impaired individuals. JAMA 1995; 273:1274–1278.
17. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s disease Centers Consortium on Apo lipoprotein E and Alzheimer’s disease. N Engl J Med 1998; 338:506–511.
18. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10:417–429.
19. Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med 2006; 57:513–533.
20. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer’s disease. Am Geriatric Psychiatry 2006; 14:561–573.
21.McShane R, Areosa Sastre A,Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; 2:CD003154.
22. Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998; 116: 331-47.
23. “Memantine.” Geriatric Lexi-Drugs Online.  http://www. Crlonline.com/crlonline    
24. Lyketsos CG, Olin J. Depression in Alzheimer’s disease: Overview and treatment. Biol Psychiatry 2002; 52:243–252.
25. Rubin CD. The primary care of Alzheimer’s disease. Am J Med Sci 2006; 332:314–333.
26. Beier MT. Treatment strategies for the behavioral symptoms of Alzheimer’s
Disease: Focus on early pharmacologic intervention. Pharmacotherapy 2007; 27:399–411
27. Antipsychotic. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical
drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355:1525–1538.
28. Benoit M, Arbus C, Blanchard F, et al. Professional consensus on the treatment of agitation, aggressive behaviors, oppositional behavior and psychotic disturbances in dementia. J Nutr Health Aging 2006; 10:410–415.
29. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58A:331–353.
30. Hebert LE, scherr PA, Bienias JL,et al. Alzheimer disease in the US population   :prevalence estimates using the 2000 census. Arch neural 2003; 60:1119-1122.
31. Irudaya rajan s, mishra US sarma PS, India’s elderly: burden or challenge, new Delhi: sage publications and London: thousand oaks 1999.
32. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, et al. (2013) The global prevalence of dementia: a systematic review and meta analysis. Alzheimer’s Dement 9: 63-75.
33. Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, et al. (2013) Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 381: 2016-2023.


SUBMIT YOUR ARTICLE/PROJECT AT editor-in-chief@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email